Special Reports

The bio/pharma industry faces challenges in growth as the world seeks to recover from the COVID-19 pandemic. Per an IQVIA analysis, drug sales in most of the world increased in…

CEOs and senior executives from DCAT Member Companies provide the latest major news from their companies impacting the bio/pharmaceutical manufacturing value chain: manufacturing expansions, mergers and acquisitions, and other key…

Development of vaccines and treatments for COVID-19 has occurred at an unprecedented pace of scientific innovation. A Pfizer executive tells the story behind how the company brought its mRNA COVID-19…

The industry has risen to a myriad of challenges due to the pandemic, but what is next in supply management? Executives from J&J and Gilead provide their views on adapting…

CPOs offer their views on how they see business continuity planning evolving in a post-pandemic world and what actions will be needed by the industry to further mitigate supply risk.…

A newly released DCAT Research & Benchmarking study details how bio/pharmaceutical companies and suppliers are managing business continuity risks resulting from the COVID-19 pandemic and how lessons learned are affecting…

An upcoming DCAT benchmarking study is examining the lessons learned and risk-mitigation practices taken by bio/pharma companies and suppliers in the wake of the COVID-19 pandemic. What best practices can…

How was the global pharmaceutical industry performing before the novel coronavirus (COVID-19) pandemic, and what now is the near- and long-term impact on industry fundamentals and growth projections? An upcoming…

How are executives from biopharma companies, CDMOs/CMOs, and suppliers confronting real and potential risks in the wake of new trade policies? A recent DCAT Benchmarking study, conducted prior to COVID-19,…

In this special issue of DCAT Value Chain Insights, we are providing information that would have been presented at the DCAT Member Company Announcement Forum at DCAT Week ’20. Originally…